Morgan Stanley Reiterates Buy Rating on Evommune, Inc.
Morgan Stanley maintains its buy rating for Evommune, Inc. with a $26 price target, a 95.64% upside from the current price.
Key Points
- Morgan Stanley reiterated its buy rating on Evommune, Inc. (NYSE:EVMN) with a $26 target price on June 30, 2026.
- Morgan Stanley's $26 price target implies 95.64% upside from Evommune, Inc.'s ($EVMN) current $13.29 share price.
- Evommune, Inc., a biotech firm focusing on chronic inflammatory diseases, traded near $15.05 on Tuesday with a market cap of approximately $906.9 million.
- Institutional investors like RA Capital Management and RTW Investments are increasing their stakes in Evommune, Inc., while analysts maintain strong buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley reiterated its buy rating on Evommune, Inc. (NYSE:EVMN) on June 30, 2026. The firm set a price target of $26 for the biotechnology company. This update reflects Morgan Stanley's continued confidence in Evommune's potential.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 30, 2026, Morgan Stanley maintained its buy rating on Evommune, Inc. with a price target of $26. This follows a series of positive analyst actions, including HC Wainwright & Co.'s reiterated buy rating with a $50 target on May 26, 2026. RBC Capital also reiterated a buy rating with a $48 target on April 10, 2026. The consensus among analysts is a strong buy, with a mean target price of $52.25 based on eight opinions.
Evommune, Inc. Stock Up 5.0%
Shares of NYSE:EVMN traded near $15.05 on Tuesday. Evommune, Inc. has a market cap of about $906.9 million. The company isn't currently profitable, so it doesn't have a meaningful P/E ratio. Its 52-week low is $13.89, and its high is $33.20. The stock's 50-day moving average is $23.10, while the 200-day moving average stands at $22.04. Evommune maintains a strong liquidity position with a current ratio of 20.36 and a quick ratio of 19.94.
$EVMN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Other Institutional Activity in Evommune, Inc.
Several institutional investors are active in Evommune, Inc. RA Capital Management, L.P. increased its holdings by 35,868 shares, ending with 3,494,638 shares valued at about $80.3 million. RTW Investments, LP also boosted its stake by 218,564 shares, reaching a total of 1,502,235 shares worth $34.5 million, marking a 17% increase. Meanwhile, JPMorgan Chase & Co raised its position by 150,519 shares, holding 1,459,420 shares valued at $32.1 million, reflecting an 11.5% increase.
About Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company based in Palo Alto, California. It focuses on developing therapies for chronic inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Led by CEO Mr. Luis C. Pena, the company employs 48 people and is working on products like EVO756 for treating CSU and AD, and EVO301 for AD and UC.
Bottom Line
Morgan Stanley's reiterated buy rating and $26 price target on Evommune, Inc. underscore the firm's positive outlook on the company's potential. Investors keep a close eye on Evommune due to its focus on innovative treatments for chronic inflammatory diseases. Institutional activity and strong analyst consensus suggest continued interest in the company's future prospects.
Get Evommune, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EVMN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.